Author

Jayesh B. Majithiya

Artios Pharma Limited (United Kingdom)ORCID 0000-0003-2944-4871Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:mouse· 1 Research Focus:perturbation response prediction· 1

Frequent Co-Authors

Alessandro CicconiiD· 1 shared Asmita Thapa· 1 shared Aurora CeruttiiD· 1 shared Bethany Rebekah Hill· 1 shared Célia GotorbeiD· 1 shared Charles Stiles· 1 shared Christopher J. GraseriD· 1 shared Daphne Adele Haas-KoganiD· 1 shared

Activity by Year

2026-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alessandro CicconiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologyScience AdvancesPeer-reviewedJun 12, 2026

SHLD2 loss is a synthetic vulnerability to Polθ inhibition combined with radiotherapy

Gonzalo Rodríguez‐Berriguete, Purusotha Thambiayah, Alessandro Cicconi…·Geoff Stuart Higgins

The paper identifies SHLD2 loss as a vulnerability that enhances radiosensitisation when combined with Polθ inhibition in cancer cells.

DOI 10.1126/sciadv.aeb4508

humangenetic perturbation / CRISPR

𝕏 PostBluesky

Cancer BiologybioRxivPreprintMay 15, 2026

H3K27M-driven hypertranscription leads to a new targetable dependency in diffuse midline gliomas

Sharmistha Pal, Heng Wang, Jacob Geisberg…·Daphne Adele Haas-Kogan

This study identifies hypertranscription as a vulnerability in H3K27M-driven diffuse midline gliomas, showing ATR inhibition effectively targets this feature in preclinical models.

DOI 10.64898/2026.05.12.724628

𝕏 PostBluesky